Guanadrel | CAS# 40580-59-4 | Antihypertensive agent

MedKoo Cat#: 576054 | Name: Guanadrel

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Guanadrel is an antihypertensive agent. In vivo, guanadrel (5 mg/kg) inhibits reflex increases in mean arterial and femoral perfusion blood pressures induced by bilateral carotid occlusion in dogs. Formulations containing guanadrel have been used in the treatment of hypertension.

Chemical Structure

Guanadrel

CAS#40580-59-4

Theoretical Analysis

MedKoo Cat#: 576054

Name: Guanadrel

CAS#: 40580-59-4

Chemical Formula: C10H19N3O2

Exact Mass: 213.1477

Molecular Weight: 213.28

Elemental Analysis: C, 56.32; H, 8.98; N, 19.70; O, 15.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Guanadrel;

IUPAC/Chemical Name

(1,4-Dioxaspiro(4.5)dec-2-ylmethyl)guanidine

InChi Key

HPBNRIOWIXYZFK-UHFFFAOYSA-N

InChi Code

InChI=1S/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)

SMILES Code

NC(=N)NCC1COC2(CCCCC2)O1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Guanadrel is an orally active postganglionic adrenergic inhibitor of spiroketal.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	140.65
	DMSO	30.0	140.65
	Ethanol	30.0	140.65

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 213.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Xian M, Li X, Tang X, Chen X, Zheng Z, Galligan JJ, Kreulen DL, Wang PG. N-hydroxyl derivatives of guanidine based drugs as enzymatic NO donors. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2377-80. doi: 10.1016/s0960-894x(01)00456-5. PMID: 11527735. 2: Hogikyan RV, Supiano MA. Arterial alpha-adrenergic responsiveness is decreased and SNS activity is increased in older humans. Am J Physiol. 1994 May;266(5 Pt 1):E717-24. doi: 10.1152/ajpendo.1994.266.5.E717. PMID: 8203510. 3: Opplt JJ, Holzberg ES. Ultracentrifugal subclasses of low and intermediate density lipoproteins. J Lipid Res. 1994 Mar;35(3):510-23. PMID: 8014586. 4: Hogikyan RV, Supiano MA. Homologous upregulation of human arterial alpha- adrenergic responses by guanadrel. J Clin Invest. 1993 Apr;91(4):1429-35. doi: 10.1172/JCI116347. PMID: 8473492; PMCID: PMC288117. 5: Supiano MA, Hogikyan RV, Morrow LA, Ortiz-Alonso FJ, Herman WH, Bergman RN, Halter JB. Hypertension and insulin resistance: role of sympathetic nervous system activity. Am J Physiol. 1992 Nov;263(5 Pt 1):E935-42. doi: 10.1152/ajpendo.1992.263.5.E935. PMID: 1443127. 6: Piepho RW, Fendler KJ. Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations. Drugs Aging. 1991 May;1(3):194-211. doi: 10.2165/00002512-199101030-00004. PMID: 1686570. 7: Supiano MA, Hogikyan RV, Stoltz AM, Orstan N, Halter JB. Regulation of venous alpha-adrenergic responses in older humans. Am J Physiol. 1991 Apr;260(4 Pt 1):E599-607. doi: 10.1152/ajpendo.1991.260.4.E599. PMID: 1850202. 8: Darga LL, Hakim MJ, Lucas CP, Franklin BA. Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension. Am J Cardiol. 1991 Mar 15;67(7):590-6. doi: 10.1016/0002-9149(91)90897-t. PMID: 2000792. 9: Sekkarie MA, Egan BM, Neubig RR, Supiano MA. Sensitization of human alpha 1- and alpha 2-adrenergic venous responses by guanadrel sulfate. Clin Pharmacol Ther. 1990 Nov;48(5):537-43. doi: 10.1038/clpt.1990.190. PMID: 2171846. 10: Halstenson CE, Opsahl JA, Abraham PA, Schwenk MH, Andreadis NA, Antal EJ, Matzke GR. Disposition of guanadrel in subjects with normal and impaired renal function. J Clin Pharmacol. 1989 Feb;29(2):128-32. doi: 10.1002/j.1552-4604.1989.tb03300.x. PMID: 2715368. 11: Kaiser DG, Vangiessen GJ, Shah JA, Weber DJ. Gas chromatographic determination of guanadrel in plasma and urine. J Chromatogr. 1988 Dec 29;434(1):135-43. doi: 10.1016/0378-4347(88)80068-9. PMID: 3243808. 12: Owens SD, Dunn MI. Efficacy and safety of guanadrel in elderly hypertensive patients. Arch Intern Med. 1988 Jul;148(7):1515-8. PMID: 3382297. 13: De Quattro V, Shkhvatsabaia IK, Iureneva AP, Salenko BB, Khramelashvili VV. Gipertrofiia levogo zheludochka i nervnyĭ tonus pri gipertonii: razlichiia v deĭstvii diuretikov i relaksatsionnoĭ terapii [Left ventricular hypertrophy and neural tonus in hypertension: differences in the action of diuretics and relaxation therapy]. Kardiologiia. 1986 Jan;26(1):34-9. Russian. PMID: 2936923. 14: Egan B, Neubig R, Julius S. Pharmacologic reduction of sympathetic drive increases platelet alpha-2-receptor number. Clin Pharmacol Ther. 1985 Nov;38(5):519-24. doi: 10.1038/clpt.1985.217. PMID: 2996819. 15: Bauer JH. Adrenergic blocking agents and the kidney. J Clin Hypertens. 1985 Sep;1(3):199-221. PMID: 2872278. 16: DeQuattro V, deGrau A, Foti A, Kim SJ, DeQuattro E, Allen J. Effects of exercise on blood pressure, plasma catecholamines, potassium and the electrocardiogram after diuretic and neural-blocking therapy for moderate hypertension. Am J Cardiol. 1985 Aug 30;56(6):39D-45D. doi: 10.1016/0002-9149(85)91114-2. PMID: 2412430. 17: Oren A, Rotmensch HH, Vlasses PH, Riley LJ Jr, Koplin JR, Latini V, Ferguson RK. A dose-titration trial of guanadrel as step-two therapy in essential hypertension. J Clin Pharmacol. 1985 Jul-Aug;25(5):343-6. doi: 10.1002/j.1552-4604.1985.tb02852.x. PMID: 4031111. 18: Finnerty FA Jr, Brogden RN. Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs. 1985 Jul;30(1):22-31. doi: 10.2165/00003495-198530010-00005. PMID: 3896742. 19: Pals DT, DeGraaf GL. Cardiovascular effects of losulazine hydrochloride, a peripheral norepinephrine-depleting agent, in nonhuman primates. J Pharmacol Exp Ther. 1985 Feb;232(2):407-12. PMID: 3968642. 20: Jiao PH, Allen JW. [Comparison on antihypertensive and cardiac effects of guanadrel and propranolol]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1985 Feb;7(1):67-8. Chinese. PMID: 3158422.